About Dr. Arezu Jahani-Asl
Dr. Arezu Jahani-Asl is an Associate Professor in the Department of Cellular and Molecular Medicine at the University of Ottawa and a member of the Brain and Mind Institute. Her research focuses on molecular mechanisms in glioblastoma and neurodegeneration, with support from CIHR, CRS, and NSERC. She has published in leading journals such as Nature Neuroscience, Molecular Cell, and Cell Reports, and her discoveries have received international media attention. Dr. Jahani-Asl has mentored over 20 trainees and actively contributes to scientific peer review, including service on CIHR and international panels. She previously held faculty positions at McGill University and completed postdoctoral training at Harvard Medical School.
Our Research
SUMMARY
Dr. Jahani-Asl’s research program is centered on developing novel therapeutic strategies for devastating brain diseases, presently with no cure. The aim is to employ state-of-art technologies to unravel the key signalling pathways that are altered in a rare population of stem cells in the diseased brain. Specifically, the research program is focused on 1) Developing new treatments to combat malignant and resistant brain tumor stem cells in glioblastoma (the most aggressive brain cancer); 2) Identifying key signaling pathways involved in the malignant transformation of neural stem cells (NSC); and 3) Defining the key molecular events involved in the reprogramming of NSC that leads to the impairment of neurodevelopmental programs and intellectual disability (ID).
Breaking Boundaries
